Ethical Concerns in Placebo-Controlled Studies: An Analytical Approach

Abstract

The fifty-second revision of the Declaration of Helsinki included a statement that proscribed, on an ethical basis, the use of placebo in clinical research when treatment is available. Scientific methods suggest that this determination could affect the validity of research in conditions that show placebo response. Researchers became concerned about the impact that this could have on the quality of drug development. Although the clarification to the Declaration of Helsinki reversed this position, the situation called for revisions to the ethical implications of the use of placebo. Most authors agree that placebo is unacceptable in life-threatening diseases or when there is a risk of irreversible damage, but other instances require evaluation on a case-to-case basis. Institutional review boards (IRBs) have to consider the principles of research ethics when deciding whether to approve or reject placebo-controlled studies. Some algorithms to review placebo-controlled studies on ethical grounds have been published Based on these efforts and the ethical and methodological considerations derived from our own IRB experiences, the authors of this paper have designed a checklist to assist IRBs in the evaluation of placebo-controlled studies. The checklist was tested in IRB meetings and modified to better reflect the needs expressed in the discussions. It has been useful in guiding deliberations and obtaining consistency in the evaluation of placebo-controlled studies.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    World Medical Association. 52nd Revision of the Declaration of Helsinki. General Assembly. Edinburgh, Scotland; October 2000.

    Google Scholar 

  2. 2.

    World Medical Association. Newsletter, October 2001. Declaration of Helsinki: Note of Clarification on placebo-controlled trials. Available at: www.wma.net/e/home.html. (Accessed October 16, 2001).

    Google Scholar 

  3. 3.

    US Code of Federal Regulations. Food and Drug Administration; 21 CFR Parts 50 and 56.

  4. 4.

    US Code of Federal Regulation. National Institutes of Health; 45 CFR Part 46.

  5. 5.

    Baruch AB. When are placebo-controlled trials no longer appropriate? Control Clin Trials. 1997;18:602–612.

    Article  Google Scholar 

  6. 6.

    Cleophas TJM, Meulen J, Kalmansohn RB. Clinical trials: specific problems associated with the use of a placebo control group. Br J Clin Pharmacol. 1997;43:219–221.

    CAS  Article  Google Scholar 

  7. 7.

    Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med. 2000;133:474–475.

    CAS  Article  Google Scholar 

  8. 8.

    Ezequiel E. The ethics of placebo-controlled trials—a middle ground. N Engl J Med. 2001;64: 915–919.

    Google Scholar 

  9. 9.

    Bostrom H. Placebo—the forgotten drug. Scand J Work Environ Health. 1997;64 Suppl 3:53–57.

    Google Scholar 

  10. 10.

    Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology. 1997;113:2021–2022.

    Google Scholar 

  11. 11.

    Villani P, Bouvenot G. Assessment of the placebo effect of symptomatic slow acting anti-arthritics. Presse Med. 1998;27:211–214.

    CAS  PubMed  Google Scholar 

  12. 12.

    Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observation from a Department of Veterans Affairs Cooperative Study. Arch Intern Med. 2000;160:1449–1454.

    CAS  Article  Google Scholar 

  13. 13.

    Brody H. The lie that heals: the ethics of giving placebos. Ann Intern Med. 1982;97:112–118.

    CAS  Article  Google Scholar 

  14. 14.

    Biller N. The placebo effect: mocking or mirroring medicine? Perspectives Biol Med. 1999;42:398–401.

    CAS  Article  Google Scholar 

  15. 15.

    Hrobjartsson A, Gotzsche PC. Early intervention in HIV infection: where are we? AIDS Res Hum Retroviruses. 1994;10:893–899.

    Article  Google Scholar 

  16. 16.

    Swartzman LC, Burkell J. Expectations and the placebo effect in clinical drug trials: Why we should not turn a blind eye to unwinding, and other cautionary notes. Clin Pharmacol Ther. 1998;64.

  17. 17.

    Chassany O, Duracinsky M. Ethics and clinical trials. Fundam Clin Pharmacol. 1999;13:437–444.

    CAS  Article  Google Scholar 

  18. 18.

    Quitkin FM. Placebos, drug effects, and study design: a clinician’s guide. Am J Psychiatry. 1999;156:829–836.

    CAS  Article  Google Scholar 

  19. 19.

    Rossner S. Sibutramine—antidepressive agent tested against obesity. Lakartidningen. 2001;64:98.

  20. 20.

    Chouinard G, Annable L, Bradwejn J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology. 1984;83:126–128.

    CAS  Article  Google Scholar 

  21. 21.

    US Food and Drug Administration. FDA talk paper T97-57. FDA Approved Sibutramine to Treat Obesity. Rockville, MD: US Department of Health and Human Services, US Food and Drug Administration; Nov 24, 1997.

    Google Scholar 

  22. 22.

    Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Witcher J, Zervas S. An open label, dose ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:251–265.

    CAS  Article  Google Scholar 

  23. 23.

    Weiner M, Weiner G. The kinetics and dynamics of responses to placebo. Clin Pharmacol Ther. 1996;60:247–254.

    CAS  Article  Google Scholar 

  24. 24.

    Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med. 2000;133:455–463.

    CAS  PubMed  Google Scholar 

  25. 25.

    Mavissakalina M. The placebo effect in agoraphobia II. J Nerv Ment Dis. 1988;176:446–448.

    Article  Google Scholar 

  26. 26.

    Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary? Schizophr Res. 1999;35:211–218,227–236.

    CAS  Article  Google Scholar 

  27. 27.

    Ellenberg S, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical Issues and Specific Cases. Ann Intern Med. 2000;133:464–470.

    CAS  PubMed  Google Scholar 

  28. 28.

    Fabre LF, Putman HP 3rd. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry. 1987;48:406–408.

    CAS  PubMed  Google Scholar 

  29. 29.

    Hasselblad V, King DF. Statistical methods for comparison to placebo in active-control trials. Drug Inf J. 2001;35:435–449.

    Article  Google Scholar 

  30. 30.

    Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Federal Register, Document 79-12065.

  31. 31.

    Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th Edition. New York, NY: Oxford University Press; 2001:9–23.

    Google Scholar 

  32. 32.

    De Abajo FJ, Gracia DM. Ethics of the use of placebo in clinical research. Investigation Sci. November 1997:90–99.

    Google Scholar 

  33. 33.

    Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394–398.

    CAS  Article  Google Scholar 

  34. 34.

    De Deyn PP, D’Hooge R. Placebos in clinical practice and research. J Med Ethics. 1996;22:140–146.

    Article  Google Scholar 

  35. 35.

    Gelmon K, Weller IV. Randomized placebo controlled trials in HIV infection: to be or not to be? Genitourin Med. 1989;65:143–145.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Aldhous P. AIDS drug tests: placebo or no placebo? Nature. 1990;64:95.

    Google Scholar 

  37. 37.

    Somberkoff MS, Hartigan PM, Hamilton JD. Ethical dilemma in continuing a zidovidune-placebo trial in symptomatic human immunodeficiency virus infection. Trans Assoc Am Physicians. 1991;104:92–96.

    Google Scholar 

  38. 38.

    Collier AC. Early intervention in HIV infection: where are we? AIDS Res Hum Retroviruses. 1994;10:893–899.

    CAS  Article  Google Scholar 

  39. 39.

    Social Sciences and Humanities Research Council of Canada Policies. Ethical conduct for research involving human subjects, Article 7.4. Ottawa, Canada: Social Sciences and Humanities Research Council; September 17, 1998.

    Google Scholar 

  40. 40.

    Draft ICH Consensus Guideline E10—Parts 2 and 3. Choice of control group in clinical trials. Good Clinical Practice J. 1999;6:38–45.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nora Cavazos MD.

Additional information

Funding for this project was provided by Western Institutional Review Board.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cavazos, N., Forster, D. & Bowen, A.J. Ethical Concerns in Placebo-Controlled Studies: An Analytical Approach. Ther Innov Regul Sci 36, 249–259 (2002). https://doi.org/10.1177/009286150203600203

Download citation

Key Words

  • Placebo
  • Ethical review
  • IRB
  • Declaration of Helsinki